A practical reference on analytical methods: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-07 and is reviewed periodically as new material appears.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
== Further reading == Isenstadt, Alex (March 18, 2025). Revenge: The Inside Story of Trump's Return to Power. Grand Central Publishing. ISBN 978-1538765517. Allen, Jonathan; Parnes, Amie (April 1, 2025). Fight: Inside the Wildest Battle for the White House. William Morrow. ISBN 978-0063438644. Whipple, Chris (April 8, 2025). Uncharted: How Trump Beat Biden, Harris, and the Odds in the Wildest Campaign in History. Harper Influence. ISBN 978-0063386211. Tapper, Jake; Thompson, Alex (May 20, 2025). Original Sin: President Biden's Decline, Its Cover-Up, and His Disastrous Choice to Run Again. Penguin Press. ISBN 979-8217060672. Dawsey, Josh; Pager, Tyler; Arnsdorf, Isaac (July 8, 2025). 2024: How Trump Retook the White House and the Democrats Lost America. Penguin Press. ISBN 978-0593832530. Wolff, Michael (February 25, 2025). All or Nothing: How Trump Recaptured America. Crown. ISBN 978-0593735381.
The Financial Times reported that "the test showed that China had made astounding progress on hypersonic weapons and was far more advanced than U.S. officials realized." During the Zapad 2021 joint strategic exercise, most of the gear comprised novel Chinese arms such as the KJ-500 airborne early warning and control aircraft, J-20 and J-16 fighters, Y-20 transport planes, and surveillance and combat drones. Another joint forces exercise took place in August 2023 near Alaska. On 24 September 2024, the PLARF performed its first intercontinental ballistic missile (ICBM) test over the Pacific Ocean since the early 1980s.
=== Cellular co-operation === P. aeruginosa relies on iron as a nutrient source to grow. However, iron is not easily accessible because it is not commonly found in the environment. Iron is usually found in a largely insoluble ferric form. Furthermore, excessively high levels of iron can be toxic to P. aeruginosa. To overcome this and regulate proper intake of iron, P. aeruginosa uses siderophores, which are secreted molecules that bind and transport iron. These iron-siderophore complexes, however, are not specific. The bacterium that produced the siderophores does not necessarily receive the direct benefit of iron intake. Rather, all members of the cellular population are equally likely to access the iron-siderophore complexes. Members of the cellular population that can efficiently produce these siderophores are commonly referred to as cooperators; members that produce little to no siderophores are often referred to as cheaters. Research has shown when cooperators and cheaters are grown together, cooperators have a decrease in fitness, while cheaters have an increase in fitness. The magnitude of change in fitness increases with increasing iron limitation. With an increase in fitness, the cheaters can outcompete the cooperators; this leads to an overall decrease in fitness of the group, due to lack of sufficient siderophore production. These observations suggest that having a mix of cooperators and cheaters can reduce the virulent nature of P. aeruginosa.
=== Detection of protein phosphorylation === Phosphorylation means the posttranslational addition of a phosphate group to specific amino acids of proteins, and such modification can lead to a drastic change in the stability or the function of a protein in the cell. Protein phosphorylation can be detected on an autoradiograph, after incubating the protein in vitro with the appropriate kinase and γ-32P-ATP. The radiolabeled phosphate of latter is incorporated into the protein which is isolated via SDS-PAGE and visualized on an autoradiograph of the gel. (See figure 3. of a recent study showing that CREB-binding protein is phosphorylated by HIPK2.)
Sources: en.wikipedia.org
=== Cannabis === Pritzker supports expanding Illinois's medical marijuana program and legalizing recreational cannabis in Illinois. In 2019, he signed into law the Illinois Cannabis Regulation and Tax Act, which effectively legalized the possession and regulated sale of marijuana for recreational purposes starting in 2020.
Fort Bragg Homepage Archived 1 November 2020 at the Wayback Machine Historical Account of the 82nd Airborne Division Archived 9 June 2017 at the Wayback Machine All American: The Story of the 82nd Airborne Division – World War II unit history booklet, 1945 82nd Airborne Combat Footage DVD World War II Normandy June 1944 82nd AB Combat Footage DVD World War II including Operation Market Garden September 1944 The 82nd Airborne Division THE 82ND AIRBORNE DIVISION The 82nd Airborne during World War II 82nd Airborne Division, NYC Victory Parade, 12 Jan 1946 The short film Big Picture: Arctic Night is available for free viewing and download at the Internet Archive. The short film Big Picture: All American is available for free viewing and download at the Internet Archive. The short film Big Picture: This is Our Strength is available for free viewing and download at the Internet Archive. The short film STAFF FILM REPORT 66-17A (1966) is available for free viewing and download at the Internet Archive. The short film STAFF FILM REPORT 66-18A (1966) is available for free viewing and download at the Internet Archive. The short film STAFF FILM REPORT 66-19A (1966) is available for free viewing and download at the Internet Archive. The short film STAFF FILM REPORT 66-20A (1966) is available for free viewing and download at the Internet Archive. The short film STAFF FILM REPORT 66-25A (1966) is available for free viewing and download at the Internet Archive. The short film STAFF FILM REPORT 66-27A (1966) is available for free viewing and download at the Internet Archive.
== Additional Union Carbide actions == The corporation denied the claim that valves on the tank were malfunctioning and claimed that documented evidence gathered after the accident showed the valve closest to the plant's water-washing operation was closed and leak-tight. Furthermore, process safety systems had prevented water from entering the tank by accident. Carbide states that all safety concerns identified in 1982 were allayed before 1984 and had nothing to do with the accident. The company admitted that safety systems in place would not have been able to prevent a chemical reaction of such magnitude from causing a leak. According to Carbide, "in designing the plant's safety systems, a chemical reaction of this magnitude was not factored in" because "the tank's gas storage system was designed to automatically prevent such a large amount of water from being inadvertently introduced into the system" and "process safety systems—in place and operational—would have prevented water from entering the tank by accident". Instead, they claim that "employee sabotage—not faulty design or operation—was the cause of the tragedy". Tactical response The company stresses the immediate action taken after the disaster and its continued commitment to helping the victims. On 4 December, the day following the leak, Union Carbide sent material aid and several international medical experts to assist the medical facilities in Bhopal.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.